Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.

PURPOSE To investigate associations between breast cancer molecular subtype and semiautomatically extracted magnetic resonance (MR) imaging features. MATERIALS AND METHODS Imaging and genomic data from the Cancer Genome Atlas and the Cancer Imaging Archive for 48 patients with breast cancer from four institutions in the United States were used in this institutional review board approval-exempt study. Computer vision algorithms were applied to extract 23 imaging features from lesions indicated by a breast radiologist on MR images. Morphologic, textural, and dynamic features were extracted. Molecular subtype was determined on the basis of genomic analysis. Associations between the imaging features and molecular subtype were evaluated by using logistic regression and likelihood ratio tests. The analysis controlled for the age of the patients, their menopausal status, and the orientation of the MR images (sagittal vs axial). RESULTS There is an association (P = .0015) between the luminal B subtype and a dynamic contrast material-enhancement feature that quantifies the relationship between lesion enhancement and background parenchymal enhancement. Cancers with a higher ratio of lesion enhancement rate to background parenchymal enhancement rate are more likely to be luminal B subtype. CONCLUSION The luminal B subtype of breast cancer is associated with MR imaging features that relate the enhancement dynamics of the tumor and the background parenchyma.

[1]  F. B. Sørensen,et al.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[3]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[4]  E Boven,et al.  Breast cancer classification by proteomic technologies: current state of knowledge. , 2014, Cancer treatment reviews.

[5]  D. D. Maki,et al.  Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. , 2012, AJR. American journal of roentgenology.

[6]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[7]  M. Giger,et al.  Cancerous breast lesions on dynamic contrast-enhanced MR images: computerized characterization for image-based prognostic markers. , 2010, Radiology.

[8]  Jeffrey D Blume,et al.  Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. , 2013, AJR. American journal of roentgenology.

[9]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[11]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[12]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[14]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jiong Wu,et al.  Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. , 2010, Oncology reports.

[16]  T. Karn,et al.  The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. , 2007, Breast.

[17]  Robert M. Haralick,et al.  Textural Features for Image Classification , 1973, IEEE Trans. Syst. Man Cybern..

[18]  James C. Bezdek,et al.  On cluster validity for the fuzzy c-means model , 1995, IEEE Trans. Fuzzy Syst..

[19]  John David Fleig,et al.  Assessment of Feasibility to Use Computer Aided Texture Analysis Based Tool for Parametric Images of Suspicious Lesions in DCE-MR Mammography , 2013, Comput. Math. Methods Medicine.

[20]  C. Balleyguier,et al.  Computed-aided diagnosis (CAD) in the detection of breast cancer. , 2013, European journal of radiology.

[21]  S Michiels,et al.  Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Anne L. Martel,et al.  Feature Selection in Computer-Aided Breast Cancer Diagnosis via Dynamic Contrast-Enhanced Magnetic Resonance Images , 2013, Journal of Digital Imaging.

[23]  L. Carey,et al.  Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. , 2009, Seminars in radiation oncology.

[24]  San-Gang Wu,et al.  Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. , 2012, Breast.

[25]  F. Vicini,et al.  Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy , 2007, Cancer.

[26]  Ben Tran,et al.  Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.

[27]  Mark Rosen,et al.  A Multichannel Markov Random Field Framework for Tumor Segmentation With an Application to Classification of Gene Expression-Based Breast Cancer Recurrence Risk , 2013, IEEE Transactions on Medical Imaging.

[28]  N. Hynes,et al.  Potential for targeting the fibroblast growth factor receptors in breast cancer. , 2010, Cancer research.

[29]  Y. Niu,et al.  A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments , 2011, Breast Cancer Research and Treatment.

[30]  Anne L. Martel,et al.  A margin sharpness measurement for the diagnosis of breast cancer from magnetic resonance imaging examinations. , 2011, Academic radiology.

[31]  Li Lan,et al.  Computerized assessment of breast lesion malignancy using DCE-MRI robustness study on two independent clinical datasets from two manufacturers. , 2010, Academic radiology.

[32]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[33]  E. Gallardo,et al.  Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. , 2007, Clinical breast cancer.

[34]  Matthijs Oudkerk,et al.  Computer-aided detection in breast MRI: a systematic review and meta-analysis , 2011, European Radiology.

[35]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Monica Morrow,et al.  Presenting Features of Breast Cancer Differ by Molecular Subtype , 2009, Annals of Surgical Oncology.

[37]  P. Sánchez‐Rovira,et al.  Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[38]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[39]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[40]  A Vignati,et al.  Computer-aided diagnosis for dynamic contrast-enhanced breast MRI of mass-like lesions using a multiparametric model combining a selection of morphological, kinetic, and spatiotemporal features. , 2012, Medical physics.

[41]  M. Giger,et al.  Computerized interpretation of breast MRI: investigation of enhancement-variance dynamics. , 2004, Medical physics.